Homologous Recombination Repair (HRR) Testing (Somatic and Germline) is a molecular profiling used to detect mutations in HRR pathway genes—such as BRCA1, BRCA2, and ATM—to guide personalized treatment strategies for prostate cancer. Identifying these mutations helps determine eligibility for targeted therapies like PARP inhibitors and supports more precise, effective care planning.
30 days upon receipt of sample in the lab.